2 results found
Mantis Biotech has secured $7.4 million in seed funding to advance its platform for creating 'digital twins' of humans. These physics-based, predictive models aim to solve the critical data availability issues in biomedical research, especially for rare diseases, by generating synthetic datasets. Currently, Mantis is applying its technology in professional sports to predict athlete performance and injury, with plans to expand into preventative healthcare and pharmaceutical research.
Billionaire-backed startup R3 Bio is developing genetically-engineered, nonsentient "organ sacks" to replace animal testing. This initiative aligns with the Trump administration's efforts to phase out animal experimentation, offering a potentially humane and effective alternative for scientific research. The company aims to eventually create human versions for personalized medical testing.
